Rationale for CD40 pathway blockade in autoimmune rheumatic disorders - The Lancet Rheumatology
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies | Cellular & Molecular Immunology
IJMS | Free Full-Text | Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells
Le rôle biologique de l'interaction du CD40L avec l'intégrine α5β1 des lymphocytes T
The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease | Journal of Cardiovascular Translational Research
Schematic presentation of CD40 and CD40L/CD154 expression on DCs and... | Download Scientific Diagram
CD40 Ligand Deficiency | BioRender Science Templates
Zooming in on dendritic cells for CD40 agonists | Nature Cancer
Immunotherapy Screening - CD40:CD40L pathway - Tebubio's blog
CD40 Signaling Pathway
Frontiers | The CD40–CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
L'axe CD40-CD40L : implications actuelles et futures en immunologie clinique - ScienceDirect
The quantity of CD40 signaling determines the differentiation of B cells into functionally distinct memory cell subsets | eLife
JCI - Progress on new vaccine strategies against chronic viral infections
Frontiers | CD40L and Its Receptors in Atherothrombosis—An Update
Anti-CD40L monoclonal IgG2b antibody | InvivoGen
The CD40/CD40L costimulatory pathway in inflammatory bowel disease | Gut
CD40: Targeting Co-Stimulatory Pathways for Cancer Immunotherapy
The CD40/CD40L costimulatory pathway in inflammatory bowel disease | Gut
CD40L and its receptors: the binding of CD40L to CD40, αIIbβ3, α5β1, or... | Download Scientific Diagram
Finding new immunotherapy targets - Immune system agonists
